Value Assessment Framework in Emerging Markets: Middle East Experience

Kasem S Akhras
Senior Director and Head, Public Affairs MENA

ISPOR European Annual Meeting – Barcelona
Arab Network Forum
November 13th, 2018

Health Care System Landscape in MENA
A Mix of Public, Private and Self-Pay Markets

Mostly Public Funding
Algeria
Tunisia
Kuwait
Iraq
Saudi Arabia
Oman
Qatar
Bahrain
Morocco
Libya
Iran

Mostly Private Funding
UAE
Jordan
Lebanon

Mostly Out-of-Pocket
Yemen
Egypt
Syria
Palestine

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Current GDP per capita (PPP US$)</td>
<td>1,300 – 124,500</td>
</tr>
<tr>
<td>Current HE, % of GDP (2017)</td>
<td>3.0 – 7.4</td>
</tr>
<tr>
<td>Government HE, % GDP</td>
<td>1.25 – 4.98</td>
</tr>
<tr>
<td>Government HE as % of current total HE</td>
<td>30.1 – 88.3</td>
</tr>
<tr>
<td>Current HE per capita (PPP US$)</td>
<td>495 – 3,900</td>
</tr>
<tr>
<td>Pharmaceutical spend, % GDP</td>
<td>0.4 – 3.5</td>
</tr>
<tr>
<td>Pharmaceutical spend, % total HE</td>
<td>11.0 – 49.0</td>
</tr>
</tbody>
</table>
VAF Goal:
Sustainable Access to High-Value Innovations for All Patients

Key Considerations for MENA: HOW, WHO, WHAT, and SO WHAT?

• Methodological Aspects
  – HOW
    – Societal vs. Patient-centric?
    – Method (CEA, QALY, MCDA)?
    – Assessment and interpretation?
  – WHAT
    – Data inputs (epi, costs, disparity, caregiver, etc)?
  – WHO
    – Government?
    – Independent?

• Contextual Considerations
  – SO WHAT?
    – Transparency, predictability
    – Sustainable Access to Innovations
    – Lack of national health system
    – System complexity
    – Affordability
    – Country vision
    – Global aspirations
    – Localization policies

Discussion

• From a Country perspective:
  – Is VAF a local priority? Why? Why not?
  – What VAF is currently being used, if any, formally or informally?
  – What are the key challenges facing countries who are using VAF?
  – How do we advance the Framework in the region?
Thank you

شكرا